7 results about "Bile salt hydrolase" patented technology

The application discloses an animal bifidobacterium producing bile salt hydrolase and application thereof in neonatal jaundice, and belongs to the technical field of microorganisms. The animal bifidobacterium lactis WXM screened by the application has the effect of relieving neonatal jaundice, can significantly improve weight loss of a jaundice individual in an early life stage, improve abnormal increase of a bilirubin level in serum, improve liver damage, improve the level of an enzyme related to liver function, the expression level of a related inflammatory factor in the liver and the expression level of an enzyme UGT1A1 related to bilirubin metabolism, and has the effect of relieving neonatal jaundice. The strain of the application has high safety and has wide application value in the fields of food, functional food, health products, medicine and the like.

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

This invention discloses the application of red ginseng polysaccharide in the preparation of pharmaceutical compositions for the prevention and treatment of inflammatory bowel disease, belonging to the field of medical formulation technology. It is the first to clearly demonstrate that red ginseng polysaccharide promotes the expression of bile salt hydrolase and 7α-hydroxysteroid dehydrogenase by targeting and upregulating the relative abundance of Bacteroides acidophilus and Clostridium lysate in the intestine, thereby driving the production of 7-ketolithocholic acid in the intestine. Through the TGR5 activation mediated by 7-ketolithocholic acid, it improves intestinal damage caused by inflammatory bowel disease, providing a solid experimental basis and theoretical support for the application of red ginseng polysaccharide in the preparation of drugs or functional foods for the prevention and treatment of inflammatory bowel disease.

Modified Christensenella minuta bile salt hydrolase (BSH) enzyme, prebiotics containing the same, engineered bacterial cells containing the modified BSH enzyme, probiotics containing engineered bacterial cells, methods of using compositions containing the modified enzyme for treating diseases and disorders, and foods are disclosed.

The invention discloses a preparation method of combined bile acid for feed, and the method comprises the following steps: S1, providing a catalyst which is whole cells of clostridium perfringens or bile salt hydrolase extracted from the whole cells of clostridium perfringens; s2, constructing a reaction system, and adding a bile acid substrate, an amino acid substrate and the catalyst into a buffer system with the pH value of 5.0-5.6; s3, under an anaerobic or micro-aerobic condition, carrying out a catalytic reaction at 35-40 DEG C to obtain a reaction solution containing the bound bile acid; and S4, carrying out post-treatment on the reaction liquid to obtain the combined bile acid product for the feed. Whole cells of clostridium perfringens or bile salt hydrolase (BSH / T) extracted from the clostridium perfringens are adopted as a catalyst, the catalyst has high catalytic activity and specificity in an acidic buffer system with the pH value of 5.0-5.6, the binding reaction of bile acid and various non-glycine / taurine amino acids can be efficiently catalyzed, the reaction conditions are mild, strong acid, strong base or high temperature and high pressure are not needed, and the method is suitable for industrial production. The method is suitable for large-scale production.

The invention discloses a bile salt hydrolase BSH mutant protein and application thereof. The mutant protein is obtained by single mutation of an amino acid sequence of wild type bile salt hydrolase as shown in SEQ ID NO.1, and a single mutation site at least comprises any one of H91R, T122G, T122R, M161L, D166S, D167S, C189K, H215F, H215Y, K265P, G279A, A301R, Y305F or S314Q. Wild type bile salt hydrolase BSH from Bifidobacterium longum is used as a research object, an amino acid sequence of the wild type bile salt hydrolase BSH is designed and modified to obtain a series of mutant proteins with improved thermal stability and catalytic activity, and the thermal stability of the mutant proteins is 1.8-3.9 DEG C higher than that of the wild type bile salt hydrolase BSH. And moreover, the catalytic activity is improved by 1.1-4.3 times compared with that of a wild type, and the catalytic activity is obviously improved on the basis of keeping the stability of a protein structure. And a key mutation target set which can be directly used is provided for subsequent protein engineering modification of the bile salt hydrolase BSH.

The application discloses lactobacillus reuteri ZY18 and application thereof as a feed additive. The lactobacillus reuteri ZY18 is obtained through isolation and screening from the excrement of weaned piglets, and is identified through morphology and molecular biology, and the microbial preservation number of the lactobacillus reuteri ZY18 is CGMCC No. 28938. The lactobacillus reuteri ZY18 has good acid production performance, has tolerance to a simulated gastrointestinal environment, can tolerate an acid or bile salt environment and has bile salt hydrolyase activity, has good safety, has good hydrophobicity and self-aggregation capacity and adhesion capacity. It is proved through experiments that the lactobacillus reuteri ZY18 has the purposes of inhibiting bacteria, promoting animal growth, improving animal intestinal inflammation and damage, improving animal antioxidant capacity and regulating animal intestinal flora, and has application prospects in preparation of feed additives or medicines.